BMO Capital Maintains Outperform on Immunogen, Raises Price Target to $26
Portfolio Pulse from richadhand@benzinga.com
BMO Capital analyst Etzer Darout maintains an Outperform rating on Immunogen (NASDAQ:IMGN) and raises the price target from $25 to $26.
August 01, 2023 | 12:14 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BMO Capital maintains an Outperform rating on Immunogen and raises the price target from $25 to $26. This could potentially lead to an increase in the stock's price.
The Outperform rating maintained by BMO Capital indicates that they expect Immunogen to do better than the market average. The increase in the price target from $25 to $26 suggests that they believe the stock is undervalued at its current price, which could lead to an increase in the stock's price as the market adjusts to this new information.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100